Cavalier Etienne
Department of Clinical Chemistry, CHU de Liège, CIRM, University of Liege, Liège, Belgium.
Clin Chem Lab Med. 2023 Jan 16;61(5):946-953. doi: 10.1515/cclm-2022-0942. Print 2023 Apr 25.
Parathyroid hormone (PTH) determination is of paramount importance for the exploration of diseases related with calcium metabolism and for the follow-up of patients suffering from bone and mineral disorders associated with chronic kidney diseases (CKD-MBD). Unfortunately, the biologically active form of PTH, i.e. 1-84 PTH, circulates in the blood stream with many fragments and post-translationally modified forms, which decreases the specificity of immunoassays. The assays used to measure PTH, either from 2nd or 3rd generation, are not standardised, which may lead to interpretation errors and clinical consequences. Reference ranges for PTH have neither been always correctly established and the stability of the peptide is also a matter of concern. Fortunately, these last years, newer techniques using mass spectrometry (either high resolution or triple quadripole) coupled with liquid chromatography have been developed, which will help to standardise the different assays. Indeed, PTH assays standardisation is one of the task of the IFCC Committee for Bone Metabolism. Such standardisation will allow a better consistency in the interpretation of the results and will promote studies aiming at the establishment of correct reference ranges.
甲状旁腺激素(PTH)测定对于探索与钙代谢相关的疾病以及对患有与慢性肾脏病相关的骨和矿物质紊乱(CKD-MBD)的患者进行随访至关重要。不幸的是,PTH的生物活性形式,即1-84 PTH,在血流中与许多片段和翻译后修饰形式一起循环,这降低了免疫测定的特异性。用于测量PTH的第二代或第三代测定方法尚未标准化,这可能导致解释错误和临床后果。PTH的参考范围并非总是正确确定,并且该肽的稳定性也是一个令人担忧的问题。幸运的是,近年来,已开发出使用质谱(高分辨率或三重四极杆)与液相色谱联用的新技术,这将有助于使不同的测定方法标准化。实际上,PTH测定标准化是国际临床化学和检验医学联合会(IFCC)骨代谢委员会的任务之一。这种标准化将使结果解释具有更好的一致性,并将促进旨在建立正确参考范围的研究。